Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04109118 · ClinicalTrials.gov registry record · Phase 2
Benzodiazepine Discontinuation in Opioid Agonist Therapy
A Phase 2 study, sponsored by Boston Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT04109118 is a Phase 2 study that has completed, run by Boston Medical Center. The registered enrollment target is 4 participants.
The verdict
NCT04109118, a Phase 2 study, has completed, sponsored by Boston Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The proposed study is a clinical trial, designed to pilot test a Distress Tolerance-Benzodiazepine Discontinuation (DT-BD) intervention for patients on opioid agonist therapy who currently use benzodiazepines. The DT-BD intervention is an adjunctive psychosocial intervention in people seeking to discontinue (BZD) use. The goal of the study is to assess the applicability and feasibility of this intervention through treatment retention and qualitative interviews with four participants who are receiving opioid agonist treatment and who regularly use BZDs.
Interventions
- BEHAVIORAL Distress Tolerance - Benzodiazepine Discontinuation (DT-BD)
- DRUG BZD discontinuation protocol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2021-03-18 |
| Est. Completion | 2021-07-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04109118
The ClinicalTrials.gov registry entry for NCT04109118 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Medical Center, which has 253 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Distress Tolerance - Benzodiazepine Discontinuation (DT-BD) is the first listed.
NCT04109118 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04109118 about?
NCT04109118 is a clinical study titled "Benzodiazepine Discontinuation in Opioid Agonist Therapy". The proposed study is a clinical trial, designed to pilot test a Distress Tolerance-Benzodiazepine Discontinuation (DT-BD) intervention for patients on opioid agonist therapy who currently use benzodiazepines. The DT-BD intervention is an adjunctive psychosocial intervention in people seeking to dis...
What is the current status of trial NCT04109118?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2021-03-18. Estimated completion is 2021-07-08.
What interventions are being tested in trial NCT04109118?
The interventions under investigation include: Distress Tolerance - Benzodiazepine Discontinuation (DT-BD) (BEHAVIORAL), BZD discontinuation protocol (DRUG).
Who is sponsoring clinical trial NCT04109118?
This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.